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Abstract Increasing evidence has shown that probably all
malignant mouse cells, even those of spontaneous sporadic
cancers, are endowed with tumor-specific antigens. Stimu-
lation of cancer growth, rather than inhibition by the
immune reaction, is seemingly the prevalent effect in the
animal of origin (the autochthonous animal). Small initial
dosages of even strong tumor antigens tend to produce
stimulatory immune reactions rather than tumor inhibition
in any animal. Thus, an immune response at a low level may
be an essential growth-driving feature of nascent cancers,
and this may be why all cancers apparently have tumor-
specific antigens. Inasmuch as a low level of immunity is
stimulatory to tumor growth while larger dosages are
inhibitory, immuno-selection via this low response may
tend to keep the antitumor immune reaction weak and at a
nearly maximal stimulatory level throughout most of a
tumor’s existence. These facts suggest that both suppression
of tumor immunity and a heightened immune reaction might
each be therapeutic although very contrasting modalities.
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Purpose and methods
We decided to reexamine the data concerning the influence
of the host’s immune capacity on papilloma incidence and
progression that had been obtained in our laboratory by two
students, Ed Andrews and the late Marc Lappe´, prior to
1972; that is, before the immuno-stimulation hypothesis
was contemplated. At that time, the major question in our
minds was how much substance the dominant theory of
immuno-surveillance of carcinogenesis might actually
have and to what extent immunity played a role in cancer
resistance. Our laboratory’s work in 1967–1971 was, in
part, designed to study the role of the immune reaction on
papilloma production and progression in mouse skin that
had been initiated with 3-methylcholanthrene (MCA) and
promoted by either isotopic syngeneic or allogeneic
transplantation of the initiated skins. This method of pro-
motion was used with the thought that there might be less
complication from systemic MCA [1].
In the Lappe´ work [1], the mice, prior to receiving
syngeneic MCA-initiated skins, were immuno-modulated
by an immuno-stimulant or immuno-suppressed by radia-
tion alone or radiation combined with thymectomy. The
results were as expected according to the surveillance
hypothesis; that is, papilloma incidence was indirectly
proportional to the degree of immuno-competency. All
malignancies arose via progression in preexisting papillo-
mas. The percentage of papillomas becoming malignant in
each successive 40-day observation period was about
13 %, regardless of the treatment group, for a total of 44
transformations among the 369 papillomas available for
study. Thus, at least over the range examined, variations in
the level of immune capacity had no effect upon the like-
lihood of a transformation in any papilloma, but transfor-
mation was directly associated with the incidence of
papillomas.
By way of contrast, in the Andrews paper, maximal
immuno-suppression was attempted in mice bearing allo-
geneic MCA-initiated skin grafts [2]; the results were not
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as anticipated. Papilloma regressions occurred, seemingly
unaffected by the lack of immunity. A total of 81 papil-
lomas were available for at least 40 days of observation,
which, according to the Lappe´ data, was expected to yield
about ten transformants. There were no malignant trans-
formations; transformation seemed to be dependent upon
the existence of the missing immune capacity.
Discussion
The first question is the extent to which these old data are
compatible with the more recently devised immuno-stim-
ulation hypothesis of oncogenesis [3–5]. This alternative to
the immuno-surveillance theory had its first solid founda-
tion in the 1972 paper that showed, in radiated/thymec-
tomized mice, that specifically immune spleen cells
admixed with tumor cells could either stimulate or inhibit
the growth of a syngeneic tumor implant depending only
upon the ratio of immune cells to tumor cells; small ratios
stimulated the growths of the admixed tumor cells, while
larger ratios were inhibitory [6]. Spleen cells harvested
from mice immunized against a different tumor had no
effect different from the effect of spleen cells obtained
from non-immunized controls.
It is clear from inspection of the IRC (Fig. 1) that the
gross data from the Lappe´ work are consistent with both
the immuno-surveillance and the immuno-stimulation
theories of tumor origin. In the surveillance theory, the
transformants would all lie somewhere on the slope near or
to the right of ‘‘e’’ on the IRC (Fig. 1) and be inhibited
almost at their inception by an immune response; in the
stimulation theory, the transformants would all lie to the
left of ‘‘c’’ where an increase in immunity (a move to
the right) would increase rather than decrease their growth.
In the Lappe´ publication, it was pointed out that a
twofold increment in malignancies correlated with a two-
fold increment in papilloma days at risk, regardless of the
immuno-competencies of the hosts. In other words, papil-
lomas were not selected either positively or negatively by
the immune response [1]. All existing papillomas had an
equal opportunity for malignant transformation in any
given 40-day time period. This suggests that the higher
incidence of papillomas in immuno-suppressed hosts was
probably unrelated to any specific immunogenicity of the
transformants. Therefore, the higher incidence of papillo-
mas in the immuno-suppressed mice may have been caused
by some environmental change (perhaps related to wound
healing) that had no direct relationship to any specific an-
ticarcinoma immunity. Specific carcinoma immunogenicity
apparently began with the malignant transformants, not in
the preceding papillomas.
The results obtained by Andrews are at odds with the
immune surveillance hypothesis. His work differed from
that of Lappe´ only in the greater degree of immuno-sup-
pression and the use of allogeneic rather than syngeneic
skin. The work seems to show that malignant transforma-
tion fails to occur in the absence of a demonstrable immune
capacity. The mice in the Andrews work were very much
more immuno-suppressed than were those in the Lappe´
work, and no immunity could be detected by several dif-
ferent procedures including the survival of the allogeneic
skin grafts themselves. Thus, the Andrews system was
presumably very near ‘‘a’’ on the IRC (Fig. 1), in contrast
to the Lappe´ papillomas, which, even in the immuno-
suppressed groups, were further to the right [2].
The regression of papillomas (80 %) in the work of
Andrews suggests, as did the work of Lappe´, that papil-
loma regression was not a result of antipapilloma immu-
nity. However, the lack of any transformation suggests that
transformation may require an immune reaction, a con-
clusion that needs confirmation, not only because of its
importance, but also owing to the limited extent of the data
and because extreme immuno-suppression might have
compromised the health of the mice.
It seems that all or perhaps almost all spontaneous,
sporadic cancers, when transplanted, engender a tumor-
stimulating immunity compatible with a very low immune
reaction (Fig. 1a–d), and none engenders an inhibitory
reaction [7]. This recent work [7] confirms the stimulation
that was observed by Hewitt et al. and which stimulation
those authors interpreted as an absence of immunity [8].
Since all immune reactions presumably begin small before
they can grow large, it is natural to hypothesize that the
initial immune reaction is always stimulatory rather than
inhibitory to oncogenesis and to speculate that active
immunity may be necessary for at least the initial growths
of most or perhaps of all cancers.
These considerations, especially in combination with the
Andrews observations, seem to make the case for the stim-
ulation hypothesis. However, it might be suggested, in sup-
port of the surveillance idea, that the high immunogenicity of
tumors induced by higher dosages of MCA might cause
Fig. 1 The IRC or immune reaction curve. Idealized depiction of the
data from [6] showing the shape of the immune reaction curve or IRC.
The letters and numerals are arbitrary aids to discussion
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incipient tumors to lie far to the right of ‘‘c’’ on the IRC
(Fig. 1). Such a conjecture is probably falsified by the
established fact, already mentioned, that even highly
immunogenic de novo tumors do not provoke, by their
growth in the original host, an inhibitory immunity. Inhibi-
tory immunity can be invoked in the animal of origin
by repeated subsequent tumor inoculations [9], but the ori-
ginal growth of the tumor in the primary host produces only
a low level of immunity that is probably stimulatory to the
tumor [10–12]. This small stimulatory degree of immunity
is apparently caused, in some unknown way, by the small
size of the initial antigen exposure [13]. Any apparent
discrepancies between the Lappe´ and Andrews results can
be reconciled by their different locations on the IRC (Fig. 1).
Possible correlates
It remains for further investigation to discover the natural
history of cancer immunity; does the immune reaction
remain low and stimulatory after the tumor’s incipiency or
does it grow with time to inhibitory levels? Certainly, the
rarity of spontaneous regression suggests that an immune
inhibition of cancer growth, if the immunity occurs natu-
rally, is seldom very effective. However, as already sug-
gested, there is evidence that cancer-specific immunity can
be induced even in the autologous animal by subsequent
massive immunizations [9].
The Kaposi sarcoma, which is common in AIDS
patients, may illuminate the role of antitumor immunity
over time. This lesion sometimes ‘‘flares’’ during anti-
AIDS therapy; apparently, the lesion grows best when the
immune competency of the patient is impaired, but not too
impaired [14]. A likely implication may be that even an
established but untransplanted viral tumor, such as the
Kaposi sarcoma, remains dependent upon a long contin-
uing, stimulatory, low level immune reaction.
Furthermore, as already mentioned, the initial growth of
a chemically induced tumor in the autologous host renders
that host resistant to subsequent attempts to induce immune
inhibition of the growth of an inoculum of the same tumor;
the result of such a challenge may, in actuality, be some
degree of overt stimulation rather than inhibition [10–12].
The lack of inhibitory immunity apparently continues for
sometime, in the animal of origin, after the tumor’s exci-
sion. This conclusion may be supported by the observation
that progression to a more virulent type of tumor among
transplanted hamster tumors appears to depend upon a
persistent stimulus by an immune reaction [15, 16] (this
paper [15] was published in a now extinct journal and is
very difficult to obtain. In essence, the authors report that
animal tumors, transplanted to hosts of varying immuno-
competence, showed that further progression was directly
proportional to the host’s competence).
As in the mouse, human premalignant lesions also seem
to await a random malignant transformation. Thus, the
smoker accumulates with every puff an increased likeli-
hood of malignancy; on cessation of smoking, the likeli-
hood of malignancy remains at an elevated constant year
after year [17]. This phenomenon suggests the persistence
of a premalignant condition, perhaps analogous to the skin
papillomas previously discussed [1].
The virus-induced hyperplastic nodules of the mouse
breast seem to show a similar persistence, through time, of
an unchanging incidence of random malignant transfor-
mation [18].
Conclusions
The evidence seems consistent with the idea that the
appearance of a new immunogen is a necessary trigger for
oncogenesis and that immunity may continue to stimulate
the growth of a cancer throughout much of the tumor’s
existence. It could be that, in any untreated cancer, because
of positive immune selection, whatever immunity exists
may usually be near the stimulatory maximum, around ‘‘c’’
on the IRC.
If most cancers are, because of immune selection, found
to gravitate to a position near ‘‘c’’ on the IRC (Fig. 1), any
degree of immune alteration, either immuno-suppression or
immuno-stimulation, might be expected to retard, to some
degree, the growth of most malignancies. However, the
incidence of some skin and lymphoreticular cancers seems
to be increased rather than inhibited in immuno-suppressed
allograft patients [19] suggesting that these tumors may
still have been around ‘‘d’’ on the IRC (Fig. 1) when
immuno-suppression occurred.
If these conjectures are correct, why did such a system
evolve? If tolerance production was the general result of small
initial doses of foreign antigen, the result would perhaps be
catastrophic for resistance to infection! However, tolerance
induction by a tiny initial exposure to antigen and then a
continued exposure might be necessary conditions to prevent
autoimmunity. Detailed speculations along these lines appear
to be premature, except possibly to stimulate thought.
Note: A somewhat similar hypothesis has been
advanced by Shevchenko et al. [20] (this paper is virtually
unattainable in the ‘‘West’’. However, we feel that it must
be mentioned since it is an excellent and extensive review
of the related ideas being pursued in slavic countries).
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